This causes both platelet activation and the initiation of a coagulation cascade.[36] It has also been reported that the use of anti-VEGF agents to treat macular edema caused by central retinal vein occlusion (CRVO) may increase the risk of retinal artery occlusion.[37] Although CRAO occurred in this case, anti-VEGF therapy may have increased the likelihood of retinal artery occlusion. The gene discussed is VEGFA; the disease is macular retinal edema.